Company Encyclopedia
View More
name
WUXI XDC
02268.HK
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China.
680.93 B
02268.HKMarket value -Rank by Market Cap -/-

Financial Score

25/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking3/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.76%A
    • Profit Margin26.08%A
    • Gross Margin36.11%C
  • Growth ScoreA
    • Revenue YoY82.28%A
    • Net Profit YoY123.55%A
    • Total Assets YoY48.84%A
    • Net Assets YoY26.54%A
  • Cash ScoreB
    • Cash Flow Margin383.39%C
    • OCF YoY82.28%A
  • Operating ScoreB
    • Turnover0.57B
  • Debt ScoreB
    • Gearing Ratio29.94%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | WUXI XDC bottom oscillation, is a short-term recovery coming?

    WuXi XDC's closing trend yesterday continued to be stuck, hovering at a low level throughout the day, with limited enthusiasm from main funds. Recently, the Hong Kong stock market's pharmaceutical service stocks have been relatively quiet in terms of news, as the market awaits clarity on industry policies, putting overall pressure on the sector. Short-term fluctuations are constrained by the main funds' wait-and-see sentiment. The company reported progress on new nodes in its R&D pipeline last week, but the market only gave a brief reaction. Current technical indicators continue to wander at the bottom, with MACD and KDJ showing no obvious turning points, and the stock price is consolidating below the 20-day and 30-day moving averages, with scarce active buying and a clear tug-of-war near the support level. For right-side trading users, only a surge in volume or new fundamental news can provide an opportunity to trigger a recovery. During the trading session, it is necessary to be cautious of the uncertainties brought by amplified fluctuations, as sudden news is the biggest variable during the consolidation period. Investors are advised to pay attention to bottom warehouse risk management, and if industry policies are implemented or cooperation progresses significantly, they can actively participate in the rebound window. In this phase, a defensive strategy should be prioritized, focusing on sensitive changes in intraday trading volume and fundamental catalysts to capture right-side recovery signals

    Technical Forecast·
    HK
    02268
    -3.22%
    Technical Forecast·
    HK
    02268
    -3.22%

    Akari Therapeutics Partners with WuXi XDC for AKTX-101 ADC Manufacturing

    Akari Therapeutics has partnered with WuXi XDC for the GMP manufacturing of its lead ADC program, AKTX-101. This collaboration supports IND-enabling activities and a planned Phase 1 clinical trial, expected in late 2026 or early 2027. The partnership combines Akari's ADC design and PH1 payload with WuXi XDC's manufacturing expertise, laying the groundwork for future projects.

    Reuters·
    US
    AKTX
    +8.93%
    Reuters·
    US
    AKTX
    +8.93%

    CMB International's Investment Ratings and Target Prices for Pharmaceutical Stocks (Table)

    Zhao Yin International published a research report, listing the investment ratings and target prices for pharmaceutical stocks as follows: Stock | Investment Rating | Target Price (HKD) 3SBIO | Buy | 37.58 GUSHENGTANG | Buy | 44.95 WUXI XDC | Buy | 74 SINO BIOPHARM | Buy | 9.4

    AASTOCKS·
    HK
    02273
    -1.24%
    HK
    02268
    -3.22%
    HK
    01177
    -0.47%
    AASTOCKS·
    HK
    02273
    -1.24%
    HK
    02268
    -3.22%
    HK
    01177
    -0.47%

    CITIC International views the pharmaceutical sector's pullback as a rebalancing of industry valuation and performance, recommending 3SBIO and others

    Zhao Yin International believes that the correction in the pharmaceutical sector is a result of the rebalancing of valuation and performance, and the trend of innovative drugs going overseas will continue in the future. The U.S. "Biodefense Act" has limited impact on Chinese CXO companies. It recommends buying 3SBIO, GUSHENGTANG, WUXI XDC, and SINO BIOPHARM

    AASTOCKS·
    HK
    02268
    -3.22%
    HK
    01177
    -0.47%
    HK
    01530
    -1.37%
    AASTOCKS·
    HK
    02268
    -3.22%
    HK
    01177
    -0.47%
    HK
    01530
    -1.37%

    Top 10 HK Stock Losers (12.12)

    CAOCAO INC(02643) fell 11.11%, with a trading turnover 182.4 Million HKD, and a year-to-date fell 1.2%. ZHIDA TECH(02650) fell 7.89%, with a trading turnover 8.7 Million HKD, and a year-to-date rose 224.6%. HEPALINK(09989) fell 7.21%, with a trading turnover 22.3 Million HKD, and a year-to-date rose 39.6%.

    Top Gainers & Losers·
    HK
    02643
    -1.82%
    HK
    02650
    0.00%
    HK
    09989
    0.00%
    Top Gainers & Losers·
    HK
    02643
    -1.82%
    HK
    02650
    0.00%
    HK
    09989
    0.00%
    © 2025 Longbridge｜Disclaimer